Recent News

• 12.20.2024 - BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points
• 12.16.2024 - BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting
• 12.10.2024 - BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting
• 11.07.2024 - BioAtla Third Quarter 2024 Financial Results and Business Highlights Conference Call

Recent Filings

• 02.07.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.07.2025 - 8-K Current report
• 12.20.2024 - EX-99.1 EX-99.1
• 12.20.2024 - 424B5 Prospectus [Rule 424(b)(5)]